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1109-9666/ª 2016 Hellenic Cardiologi
license (http://creativecommons.org/Abstract Introduction and objectives: Primary percutaneous coronary intervention infarc-
tion became the preferred method of treatment for myocardial ST segment elevation.
Improved safety was reported in transradial access (radial) compared to transfemoral access
(femoral). The aim of this study was to compare the cost between the two access points in
ST segment elevation myocardial infarction.
Methods: This is a subanalysis of the OCEAN RACE trial in which 103 myocardial infarction pa-
tients were randomized to either the radial (nZ52) or femoral (nZ51) groups. The clinical
safety and efficacy were recorded during the hospital stay. The procedural metrics were
meticulously logged, and costs were evaluated using the micro-cost method. The indirect costs
were estimated using the human capital approach.
Results: Clinical success was numerically higher in the radial group (90.4 vs. 80.4%, pZ0.123).
There were no differences in major adverse cardiac events (9.6% vs. 11.8%, pZ0.48) and death
(2.0% vs. 6.0%, pZ0.31). The average in-hospital cost per patient was 2,740  1,092 EUR. The
cost of therapeutic success was lower in the radial group at 3,060 EUR vs. 3,374 EUR. The in-
direct costs related to absence at work were 138 EUR per patient, which were lower in the
radial group compared to the femoral group.
Conclusions: The total in-hospital costs were similar between the study groups. The indirect
costs were lower in the radial group. Introduction of radial access as the default approach
in all centers may significantly reduce the overall financial burden from a social perspective.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
The primary percutaneous coronary intervention (PCI) in ST
segment elevation myocardial infarction (STEMI) accounted
for 36% (nZ28,278) of all interventions in acute coronary
syndrome in Poland in the year 2012.1 The transradial (TR)y of Hellenic Cardiological
.06.005
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).approach became a default strategy for many independent
operators in Poland, which is consistent with current Eu-
ropean Society of Cardiology recommendations.2 Improved
safety of TR procedures compared to transfemoral (TF) was
demonstrated.3 The first feasibility reports emerged in the
90s and TR was used in selected patients with extensive
aorto-iliac disease, severe tortuosity of the aorta or other
anatomical contraindications for TF access.4 The radial
artery, unlike the femoral or brachial artery, is not an end-
artery. Therefore, even when the radial artery is occluded,
adequate ulnar artery collaterals can salvage the hand from
ischemia. It is an easy artery to compress and sheath
removal results in diminished risk of bleeding and other
vascular complications.5 Yet, the smaller radial artery size,
weaker pulse and more tortuosity may contribute to
increased procedural metrics, including time in the cathElsevier B.V. This is an open access article under the CC BY-NC-ND
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Letter to the Editor 199lab, contrast volume and radiation exposure. The decision
regarding transition of the entire spectrum of interventions
towards a TR strategy must take into consideration the
economic burden from local and social perspectives as well.
In patients undergoing diagnostic catheterization or elec-
tive PCI there is a cost-benefit for TR access.6 Whether the
cost-effectiveness is also true for TR in primary PCI in STEMI
patients has not been demonstrated yet.
The aim of this study was to assess costs and cost-
effectiveness of TR compared to TF access in a STEMI
population treated with primary PCI. To study this proce-
dure, we designed a prospective randomized controlled
trial with a predefined economic study protocol. The clin-
ical results of the “Access for percutaneous coronary
intervention in STEMI: radial vs. femoral - prospective,
randomized clinical trial” (OCEAN RACE trial) have been
published, and in this paper, we disclose the pharmacoe-
conomic subanalysis.7
2. Methods
The study population comprised 103 STEMI patients. A
detailed description of the methodology and study flow
were published with the clinical results of the OCEAN RACE
trial.7 In brief, the baseline characteristics of the two study
groups are presented in Table 1. Patients were treated
according to ESC STEMI guidelines.8
The cost-effectiveness analysis was performed from two
perspectives: a hospital perspective with direct medical
and nonmedical costs included and a societal perspective
with indirect costs.
Clinical efficacy was defined in regard to angiographic
success (a Thrombolysis in Myocardial Infarction flow of 3
and residual stenosis less than 20%) and clinical success
(angiographic success, survival to hospital discharge, no
major adverse cardiac events).
The following procedural metrics were recorded: angi-
ography and angioplasty time, contrast volumes and ma-
terials used (including stents, balloons, wires, sterile
gowns, local anesthetics and catheters for intra-aortic
balloon pumps). The in-hospital time was calculated. Un-
planned diagnostics, consultations and interventions driven
by periprocedural complications were reported. We used
the micro-cost method for collecting data on the resources
that were utilized and the value of those resources. The
indirect costs were estimated in regard to the patients’
absence from work (absenteeism) by using the humancapital approach. The value of the daily gross domestic
product per capita (2012) was obtained from macroeco-
nomic reports provided by the Polish Central Statistical
Office.9 All costs were reported in Polish zloty (PLN) and
converted to EUR for the purpose of clarity. The conversion
rate was 1 EUR Z 4.24 Polish zloty.
In the cost-effectiveness analysis, we matched clinical
efficacy with in-hospital costs and calculated the cost of
therapeutic success (total cost/clinical efficacy) as well as
the incremental cost-effectiveness ratio (D total cost/D
clinical efficacy).
To understand how the choice of vascular access in
STEMI patients may impact the national economy, we
extrapolated the indirect costs onto the entire population
by assuming that all primary PCI in STEMI were performed
from TR access. The in-direct costs were calculated based
on the daily value of gross domestic product per capita,
which was multiplied by the average length of an in-
hospital stay in each study arm. The difference was then
presented as an in-direct cost benefit. All pharmacoeco-
nomic analyses were performed with intention-to-treat
results from RCT.
We used Student’s t-test, the Kruskal-Wallis test, a chi-
square test and Fisher’s exact probability test to compare
the TR arm vs. the TF arm. Data are presented as the mean
values, median and hazard ratios with a 95% confidence
interval (95% CI). P-values of less than 0.05 were considered
to be statistically significant. The study was initiated and
funded by investigators. The investigators followed the
Consolidated Health Economic Evaluation Reporting Stan-
dards statement.10
3. Results
Patients were equally distributed in the study arms (TR:52/
TF:51), and the baseline clinical characteristics did not
differ between the groups. Angiographic success was ach-
ieved in 98.1% (TR) vs. 92.2% (TF) of cases, p Z 0.205. In
99% of cases, the operator successfully crossed the occlu-
sion with a guidewire and was able to achieve reperfusion.
There were no differences between the groups in terms of
the baseline Thrombolysis in Myocardial Infarction flow.
Clinical success was achieved in 85.4% of cases and was
numerically higher among individuals in the TR group (TR:
90.4 vs. 80.4%, p Z 0.123). Clinical success was mainly
driven by numerically higher angiographic success in the TR
group, as reported previously. 7 The average in-hospital
stay was 8.37  5.77 days.
The average in-hospital cost per STEMI patient was
2,740  1,092 EUR. The medical costs accounted for 85.5%
of total costs (2,217836 EUR). Overall, 52.7% of medical
costs were associated with the Acute Coronary Unit and
post-procedural pharmacotherapy (1,445739 EUR). The
procedural costs included diagnostic and angioplasty cath-
eters, guidewires, balloons and stents, which comprised
21.2% of medical costs (581338.5 EUR). There was a small
cost difference in the total medical costs: 2,740 EUR in the
TR group and 2,686.8 EUR in the TF group. The breakdown
of costs is presented in Table 2.
The cost-effectiveness was analyzed in relation to in-
hospital costs and clinical efficacy. The cost of clinical
Table 1 Baseline clinical characteristics of patients on admission.
Radial access (nZ52) Femoral access (nZ51) p
Age e years 61 (49.7e72.2) 62.8 (50.2e75.4) 0.44
Height e cm 170.4 (163.2e177.7) 169.2 (159.9e178.5) 0.48
Weight e kg 76 (60.5e91.5) 77.8 (62.9e92.7) 0.57
BMI e kg/m2 26 (21.7e30.2) 27 (22.7e31.3) 0.21
BSA e m2 1.89 (1.659e2.116) 1.89 (1.674e2.104) 0.95
Pulse e bpm 82 (60.8e103.0) 78 (58.5e97.1) 0.30
Systolic blood pressure e mm Hg 140.5 (110.2e170.8) 132.2 (107.1e157.3) 0.14
Diastolic blood pressure e mm Hg 77.5 (59.1e95.9) 70.8 (55.8e85.9) 0.05
Hypertension 69.8% 68.2% 1.00
Diabetes type 2 18.2% 27.7% 0.33
Previous MI 7.7% 8.3% 1.00
Hyperlipidemia 69.2% 75.0% 0.66
Chronic kidney disease 12.0% 18.4% 0.41
Peripheral artery disease 13.2% 15.4% 1.00
Smoking 65.3% 66.7% 1.00
Oral anticoagulation 2.6% 0.0% 0.49
Dysthyroidism 10.0% 12.5% 1.00
Carotid artery stenosis 7.9% 5.1% 0.66
Hemoglobin e g/dL 13.7 (12.2e15.2) 13.9 (12.5e15.3) 0.45
Platelets e 103/ml 235.1 (169.2e301.0) 226.5 (157.3e295.7) 0.52
Troponin e ng/ml 6.5 (0.00e18.17) 20.4 (0.00e77.28) 0.09
Creatinine e mg/dl 1.0 (0.6e1.4) 1.0 (0.6e1.4) 0.46
eGFR e mL/min./1.72 m2 86.5 (62.4e110.6) 87.9 (59.7e116.2) 0.79
Total cholesterol e mg/dL 201 (153.3e248.7) 197.6 (155.7e239.4) 0.71
LDL-C e mg/dL 128.4 (89.4e167.4) 121.9 (82.1e161.7) 0.43
HDL-C e mg/dL 42.6 (26.7e58.5) 44.4 (30.5e58.3) 0.56
Triglycerides e mg/dL 169.3 (31.8e306.8) 144.7 (70.1e219.3) 0.28
Values are presented as averages (95% confidence interval) if not indicated otherwise; BMI - body mass index; BSA - body surface area; MI
- myocardial infarction; eGFR - estimated glomerular filtration rate; LDL-C e low density lipoprotein cholesterol; high density lipo-
protein cholesterol; HDL e high density lipoprotein cholesterol.
200 Letter to the Editorsuccess was lower in the TR group (3,060 EUR vs. 3,374
EUR). The incremental cost-effectiveness ratio was 540 EUR
per clinical success.
The average in-hospital expenditures related to com-
plications included diagnosis and treatment costs. Both
were relatively low and amounted to 3.9 EUR (TR: 2.714.6
EUR vs. TF: 5.120.7 EUR) and 50 EUR (TR: 48.027.8 EUR
vs. TF: 52.447.6 EUR) per patient, respectively.
The value of the Polish annual gross domestic product
during the study period was 363,019  106 EUR. The
average daily value of gross domestic product per capita
was 61.4 EUR. The average length of in-hospital stay was
significantly shorter in the TR arm vs. the TF arm (7.2 days
vs. 9.45 days, p<0.05). The corresponding indirect costs
per patient were 138 EUR lower in the TR arm than in the TF
arm (442 EUR vs. 580 EUR; Table 3). If all of the PCI in STEMI
patients (28,060 procedures per year) were performed from
a radial approach, the yearly savings from indirect costs
would reach 2.58 x 106 EUR.
4. Discussion
The number of pharmacoeconomic publications assessing
PCI in the STEMI population is limited, and we have not
found a single cost analysis based on a randomized control
trial comparing TR vs. TF in a STEMI population.One of the first studies that assessed the costs of non-
acute PCI in relation to vascular access was published by
Mann et al.11 They showed that the TR approach was sub-
stantially less expensive than the TF approach because of
lower supply costs and fewer access complications. The au-
thors suggested that that theTRapproach should become the
dominant strategy for coronary stenting because the
approach offered better outcomes at a lower cost.
A study of paramount importance conducted in 2007
addressed the problem of cost-effectiveness from the TR
approach by comparing it with TF access performedwith and
without closure device.12 The equipment cost was higher in
the TR group compared to the TF group without a vascular
closure device (93.0  9.5 USD vs. 40.5 USD, p<0.001) but
lower than costs in the TF group with a vascular closure de-
vice (19.7 12.7USD vs. 31.1 9.3USD, p< 0.001). The total
variable procedural cost was lower for the TR group than the
cost for both TF groups, which was mainly driven by lower
recovery costs in the TR group associated with shorter stays
in the recovery room (369.5 USD 74.6 vs. 446.9 USD 60.2
and 553.4 USD  81.0; p < 0.001). These findings were
consistent with our results, although there are some crucial
differences between the two studies. The previous studywas
not dedicated to STEMI, and itwas conducted in theUShealth
care system.Additionally, the authors did not assess the total
length andcost of the hospital stays, and theydid not analyze
Table 2 In-hospital costs













Total cost 2,740  744.5 1,177.8 4,847.6 2,686.8  1,316.8 979.7 9,925.5 0.80
Medical costs 2,343.9  579.8 94.3 990.6 2,296.5  1027.2 47.2 2,311.3 0.77
Hospital stay and
pharmacotherapy
1,469.3  555.1 1,083.5 3,857.1 1,421.7  889.9 932.5 7614.2 0.87




566.7  308.33 16.3 265.3 585.6  363.6 17 371.5 0.78
Periprocedural
pharmacotherapy
149.8  149.6 24.8 1,726.7 142.9  147 24.8 1,818.6 0.82
Unplanned diagnostics 17.9  27.6 0 318.6 17.9  22 0 320.8 0.99
Non-medical costs 396.5  199.5 0 681.1 390.3  319.4 0 138.9 0.91
SD e standard deviation; EUR e Euro; Conversion rate: 1 EUR Z 4.24 Polish zloty.


























pPCI e primary percutaneous coronary intervention; EUR e
euro.
Conversion rate: 1 EUR Z 4.24 Polish zloty.
*nZ52; **nZ51.
Letter to the Editor 201the indirect costs as well as the impact on the social cost
burden.
The recently published analysis by Applegate et al.
evaluated the costs related to TR vs. TF coronarography.
The radial strategy was associated with a cost-benefit of
228 USD per procedure per patient (TR: 8,888  7,994 USD
vs. TF: 9,116  8,299 USD). 13 The observed difference was
mainly derived from shorter in-hospital stays, and the
procedure-related costs were 17 USD higher in the TR
group. A retrospective analysis of data from 20% of all un-
selected PCI gathered in the American PREMIER registry
showed similar results.14 The total in-hospital costs were
553 USD lower in the TR group [TR: 11,736 USD (95% CI:
11,200 e 12,272 USD) vs. 12,288 USD (95% CI: 12,102 e
12,474 USD), pZ0.03]. Cooper et al. performed a ran-
domized study assessing the cost and quality of life in pa-
tients who received coronary angiograms from TR vs. TF
access.15 The radial approach was associated with a markeddecrease in hospitalization and in-hospital pharmaco-
therapy costs (TR: 2,010 USD vs. TF: 2,299 USD, p<0.0001).
There was also a significantly shorter hospital stay in the TR
arm (TR: 3.6 days vs. 10.4 days, p<0.0001). Of note, the
procedure, material and periprocedural pharmacotherapy
costs were equivalent between the groups. These obser-
vations are similar to those reported in our study.
In our study, the total costs were mainly driven by hos-
pitalization, pharmacotherapy (52.7%) and procedure costs
(21.2%). As reported by the Dutch researchers who analyzed
the costs in a STEMI population, the hospitalization costs
corresponded to 35% of total costs (2,030  3,679 EUR) and
procedural costs corresponded to 24% of total costs (1,187
 2,172 EUR). The authors did not distinguish the costs
according to vascular access type; however, they clearly
showed a strong correlation between the length of hospital
stay and the total cost. Diagnostic procedures performed
from radial access allow for same-day discharge, which is
the most cost-effective approach.
We have not found any publications evaluating indirect
costs in STEMI patients treated from a TR vs. TF access
point. There are different approaches to estimate the in-
direct costs in healthcare. For the purpose of our study, we
used the human-capital approach based on the length of
hospitalization and gross domestic product per capita as a
unit cost source for productivity lost. Due to the lack of
reliable data regarding the period of sick leave after hos-
pitalization, sick leave was not included in the analysis.
This may be a limitation that led to an underestimation of
the real indirect cost impact. The presented results are
based on a subanalysis of the OCEAN RACE trial in which the
sample size analysis was based on clinical, not pharma-
coeconomic, assumptions.
There is no doubt that the TR approach provides clear
safety and efficacy advantages over the TF strategy, which
was confirmed by multiple randomized trials and elegantly
summarized in a 3,347-patient meta-analysis that showed
shorter hospital stays, lower risk of major/minor bleeding
and lower short-term mortality associated with the TR
approach.16 These clinical benefits translate directly into
202 Letter to the Editoreconomic advantages for TR approach, which were
confirmed by our study.17
5. Conclusions
The TR approach is associated with a lower cost of thera-
peutic success, shorter length of hospital stays and lower
indirect costs. Introduction of TR access as the default
approach in all STEMI centers may significantly reduce the
overall financial burden. These results can be used to sup-
port a local decision on the best approach for PCI.
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